Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Oxford Nanopore Technologies Ltd

Healthcare GB ONT

140.0GBX
5.50(4.09%)

Last update at 2026-06-04T15:41:00Z

Day Range

132.20141.20
LowHigh

52 Week Range

104.00224.80
LowHigh

Fundamentals

  • Previous Close 134.50
  • Market Cap1055.31M
  • Volume2067579
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-115.60000M
  • Revenue TTM223.90M
  • Revenue Per Share TTM0.23
  • Gross Profit TTM 136.40M
  • Diluted EPS TTM-0.15

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -139.90000M -139.94300M -149.76800M -83.41100M -166.00400M
Minority interest - - - - -
Net income -145.20000M -146.18800M -154.50700M -91.02500M -167.61300M
Selling general administrative - 158.81M 155.25M 157.45M 161.75M
Selling and marketing expenses - - 1.31M - -
Gross profit 131.30M 105.39M 90.48M 123.81M 73.19M
Reconciled depreciation - 43.28M 41.63M 31.87M 24.69M
Ebit -155.30000M -136.37800M -147.33400M -98.47900M -164.53300M
Ebitda -105.50000M -93.09400M -105.70700M -60.90500M -139.17800M
Depreciation and amortization 49.80M 43.28M 41.63M 37.57M 25.36M
Non operating income net other - - - - -
Operating income -155.30000M -152.33300M -168.60900M -98.47900M -164.53300M
Other operating expenses 379.20M 335.52M 338.28M 297.08M 298.19M
Interest expense 2.80M 3.56M 2.21M 1.63M 0.91M
Tax provision - 6.23M 4.74M 7.61M 1.61M
Interest income - 14.84M 18.85M 5.94M 0.22M
Net interest income - 11.28M 16.65M 4.31M -0.68400M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 5.30M 6.23M 4.74M 7.61M 1.61M
Total revenue 223.90M 183.19M 169.67M 198.60M 133.66M
Total operating expenses 286.60M 257.73M 259.09M 222.29M 237.73M
Cost of revenue 92.60M 77.80M 79.19M 74.79M 60.47M
Total other income expense net 15.40M 12.39M 18.84M 15.07M -1.47100M
Discontinued operations - - - - -
Net income from continuing ops - -146.18800M -154.50700M -91.02500M -167.61300M
Net income applicable to common shares - - - -91.02500M -167.61300M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 622.50M 742.05M 777.06M 823.89M 841.87M
Intangible assets - 2.05M 2.14M 30.04M 23.00M
Earning assets - - - - -
Other current assets 16.60M 12.92M 41.76M 2.06M 69.07M
Total liab 159.20M 155.71M 133.21M 130.33M 137.89M
Total stockholder equity 463.30M 586.34M 643.85M 693.56M 703.98M
Deferred long term liab - - - 29.69M 22.61M
Other current liab 60.00M 74.83M 55.88M 64.38M 81.95M
Common stock 0.10M 0.10M 0.09M 0.08M 0.08M
Capital stock - 0.10M 0.09M 0.08M 0.08M
Retained earnings -550.90000M -401.96200M -257.71400M -105.99100M -15.90200M
Other liab - - - 8.75M 10.65M
Good will - - - - -
Other assets - - 10.37M 7.68M 28.68M
Cash 181.10M 199.52M 220.54M 356.78M 487.84M
Cash and equivalents - - - - -
Total current liabilities 118.00M 111.49M 89.20M 102.53M 105.05M
Current deferred revenue 34.40M - 15.16M - -
Net debt -139.60000M -153.55300M -178.88100M -322.68000M -463.03600M
Short term debt 5.20M 5.36M 8.64M 15.05M 2.61M
Short long term debt - - - - -
Short long term debt total 41.50M 45.96M 41.66M 34.10M 24.80M
Other stockholder equity 786.40M 779.70M 698.55M 799.46M 719.80M
Property plant equipment - - - 63.20M 61.92M
Total current assets 420.00M 520.10M 447.18M 638.00M 750.61M
Long term investments - - - - -
Net tangible assets - - - 693.21M 703.58M
Short term investments 74.20M 138.85M 49.51M 119.41M 130.63M
Net receivables 66.60M 69.35M 33.83M 38.10M 60.97M
Long term debt - - - 0.00000M 9.50M
Inventory 81.50M 99.45M 101.55M 87.70M 63.07M
Accounts payable 18.40M 31.30M 25.18M 23.10M 20.49M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 227.70M 208.51M 202.93M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 53.20M 44.40M 20.40M 119.41M 130.63M
Deferred long term asset charges - - - - -
Non current assets total 202.50M 221.96M 329.88M 185.89M 91.26M
Capital lease obligations - 45.96M 41.66M 34.10M 15.30M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 15.03M -61.79400M -65.79400M -131.37500M
Change to liabilities - - - 4.43M 33.57M
Total cashflows from investing activities 48.50M 15.03M -61.79400M -65.79400M -161.98500M
Net borrowings - - 0.00000M -13.61100M -2.36100M
Total cash from financing activities -2.10000M 73.58M 64.73M -13.71500M 622.90M
Change to operating activities - - - - -
Net income -145.20000M -146.18800M -154.50700M -83.41100M -166.00400M
Change in cash -18.41700M -21.01900M -136.24200M -131.06200M 406.98M
Begin period cash flow 199.52M 220.54M 356.78M 487.84M 80.86M
End period cash flow 181.10M 199.52M 220.54M 356.78M 487.84M
Total cash from operating activities -62.80000M -109.88500M -137.30200M -49.38700M -53.82600M
Issuance of capital stock - 83.23M 71.60M 3.75M 642.14M
Depreciation 49.80M 43.28M 41.63M 31.87M 24.69M
Other cashflows from investing activities - 28.97M -4.48600M 3.44M 0.21M
Dividends paid - - - - -
Change to inventory 4.90M -21.17600M -43.06000M -24.71700M -27.44400M
Change to account receivables -9.40000M -1.82500M 0.12M -7.40200M 10.89M
Sale purchase of stock - - - - -
Other cashflows from financing activities -8.70000M -2.64500M -2.57200M -7.96600M -19.23900M
Change to netincome - - - 37.45M 72.08M
Capital expenditures 3.50M 13.94M 27.29M 42.23M 30.82M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 2.10M -23.00100M -41.44000M -27.68500M 17.02M
Stock based compensation - 3.92M 34.91M 48.78M 62.45M
Other non cash items 30.50M 12.10M -17.89000M -18.94600M 0.68M
Free cash flow -66.30000M -123.82800M -164.59200M -91.62100M -84.64300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ONT
Oxford Nanopore Technologies Ltd		 5.50 4.09% 140.00 - - 4.71 2.50 4.23 -8.8899
GNS
Genus PLC		 38.00 1.70% 2274.00 36.08 26.18 2.53 3.46 2.92 15.38
OXB
Oxford BioMedica PLC		 28.00 4.90% 600.00 - 208.33 4.05 7.60 4.42 308.96
AVCT
Avacta Group PLC		 - -% 70.00 - - 2849.46 1929.84 2525.51 -12.0368
IBT
International Biotechnology Trust plc		 28.00 2.99% 966.00 - 714.29 16.40 1.20 15.60

Reports Covered

Stock Research & News

View All

Profile

Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows the real-time analysis of DNA or RNA. It offers MinION Mk 1D, a portable device for DNA and RNA; GridION and GridION Q, a compact bench top device, which delivers a version of hardware, software, and chemistry. The company also provides PromethION 2 Solo, PromethION 2, PromethION 24, and PromethION 48. Its platform enables its customers to perform scientific/biomedical research in a various area, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. It operates in the Americas, Europe, the Middle East, Africa, India, and the Asia Pacific. The company was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies plc in May 2008. Oxford Nanopore Technologies plc was incorporated in 2005 and is headquartered in Oxford, the United Kingdom.

Oxford Nanopore Technologies Ltd

Gosling Building, Oxford, United Kingdom, OX4 4DQ

Key Executives

Name Title Year Born
Dr. Gordon S. Sanghera Co-Founder, CEO & Director NA
Prof. Hagan Bayley Ph.D. Co-Founder & Member of Technical Advisory Board NA
Mr. Tim Cowper CFO & Director NA
Mr. Rhodri Davies VP of Operations NA
Mr. Clive G. Brown CTO & Director NA
Mr. John Schoellerman Sr. VP of Corp. Devel. & Investor Relations NA
Mr. Jordan Herman Sr. VP & Gen. Counsel NA
Mr. Richard Compton Sr. VP of Sales & Commercial Operations NA
Ms. Sara Agee Le VP of Global Marketing NA
Ms. Sarah Lapworth VP of Global HR NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.